Short Interest in Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) Expands By 14.8%

Posted by Nicole Kennedy on Apr 30th, 2024

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO – Get Free Report) was the target of a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 510,400 shares, a growth of 14.8% from the March 31st total of 444,600 shares. Approximately 2.9% of the company’s stock are short sold. Based on an average daily volume of 502,300 shares, the days-to-cover ratio is currently 1.0 days.

Cardio Diagnostics Stock Performance

NASDAQ CDIO traded up $0.01 during trading hours on Monday, reaching $0.70. 541,797 shares of the company were exchanged, compared to its average volume of 935,276. Cardio Diagnostics has a 1 year low of $0.17 and a 1 year high of $3.56. The business’s 50 day simple moving average is $1.30 and its 200-day simple moving average is $1.54.

Institutional Investors Weigh In On Cardio Diagnostics

An institutional investor recently bought a new position in Cardio Diagnostics stock. Vontobel Holding Ltd. bought a new position in Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 12,000 shares of the company’s stock, valued at approximately $30,000. Vontobel Holding Ltd. owned 0.06% of Cardio Diagnostics as of its most recent SEC filing. Institutional investors and hedge funds own 8.06% of the company’s stock.

Analyst Ratings Changes

Separately, Benchmark reduced their price target on shares of Cardio Diagnostics from $4.00 to $1.35 and set a “speculative buy” rating for the company in a research report on Friday, April 19th.

Check Out Our Latest Stock Report on Cardio Diagnostics

Cardio Diagnostics Company Profile

(Get Free Report)

Cardio Diagnostics Holdings, Inc, an artificial intelligence-powered precision cardiovascular medicine company, develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease.